Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Blood (2023) 142 (7): 621–628.

https://doi.org/10.1182/blood.2023020244

Published: 2023

Journal Articles

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Martine Bagot, Youn H. Kim, Pablo L. Ortiz-Romero, Pier Luigi Zinzani, Neha Mehta-Shah, Olivier Dereure, Marie Beylot-Barry, Stéphane Dalle, Eric D Jacobsen, Auris Huen, Andrea Combalia, Maxime Battistella, Alejandro A. Gru, Hélène Moins-Teisserenc, Michael S. Khodadoust, Julien Viotti, Christine Paiva, Marianna Muller, Pierluigi Porcu

Blood (2022) 140 (Supplement 1): 3760–3761.

https://doi.org/10.1182/blood-2022-160239

Published: 2022

Journal Articles

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 2253–2255.

https://doi.org/10.1182/blood-2022-162583

Published: 2022

Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6531–6533.

https://doi.org/10.1182/blood-2022-159823

Published: 2022

Journal Articles

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Ann S. LaCasce, David C. Fisher, Alex F. Herrera, Caron A. Jacobson, Austin I. Kim, Reid W Merryman, Oreofe O. Odejide, Samuel Ng, Yago Nieto, Craig S. Sauter, Gunjan L. Shah, Jasmine Zain, Philippe Armand, Eric D Jacobsen

Blood (2022) 140 (Supplement 1): 1185–1187.

https://doi.org/10.1182/blood-2022-164839

Published: 2022

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 9387–9389.

https://doi.org/10.1182/blood-2022-169432

Published: 2022

Journal Articles

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Blood (2022) 140 (Supplement 1): 10976–10978.

https://doi.org/10.1182/blood-2022-162944

Published: 2022

Journal Articles

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Steven M. Horwitz, Kerry J. Savage, Tim Illidge, Swaminathan P Iyer, Ranjana Advani, Andrei R Shustov, Nancy L. Bartlett, Barbara Pro, Eric D Jacobsen, Raphael Koch, Domingo Domenech Eva, Michelle A. Fanale, Keenan Fenton, Frank Campana, Cassie Dong, Lorenz Truemper

Blood (2021) 138 (Supplement 1): 135.

https://doi.org/10.1182/blood-2021-145124

Published: 2021

Journal Articles

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2021-147263

Published: 2021

Journal Articles

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Neha Mehta-Shah, Eric D Jacobsen, Todd A. Fehniger, Brad S. Kahl, Nancy L. Bartlett, Amanda F. Cashen, Armin Ghobadi, Beth Reagan, Anne Fischer, Alison J. Moskowitz, Fei Wan, Austin Jacobsen, Meredith Olson, Edgar Vigil, Natalie Hill, Karina Elias, Ying Huang, Steven M. Horwitz

Blood (2021) 138 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2021-148768

Published: 2021

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

Jonathan E Brammer, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Eric D Jacobsen, Giuseppe Gritti, Debra Litwak, David Cohan, Danica J Katz, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2021) 138 (Supplement 1): 2456.

https://doi.org/10.1182/blood-2021-148939

Published: 2021

Journal Articles

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Blood (2021) 137 (10): 1353–1364.

https://doi.org/10.1182/blood.2020006464

Published: 2021

Includes: Supplemental data

Journal Articles

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138542

Published: 2020

Journal Articles

End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Neha Mehta-Shah, MD, Todd A Fehniger, MDPhD, Eric D Jacobsen, MD, Katrina Peterson, Brad S. Kahl, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Armin Ghobadi, MD, Anne Fischer, BS, Beth Reagan, Alison J. Moskowitz, MD, Fei Wan, Ying Huang, PhD, Kasey Hutt, PhD, Edgar Vigil, Meredith Olson, Austin Jacobsen, Steven M. Horwitz, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138768

Published: 2020

Journal Articles

Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-135919

Published: 2020

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4019.

https://doi.org/10.1182/blood-2019-125017

Published: 2019

Journal Articles

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Austin I Kim, MD, Reid W Merryman, MD, Jessica Lowney, Josie Montegaard, NP, Victoria Patterson, RN, Caron A. Jacobson, MD, Eric D Jacobsen, MD, Ann S. LaCasce, MD MMSc, Jon E. Arnason, MD, Philippe Armand, MD PhD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 32.

https://doi.org/10.1182/blood-2019-127506

Published: 2019

Journal Articles

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Steven M. Horwitz, MD, Neha Mehta-Shah, MD, Barbara Pro, MD, Eric D Jacobsen, MD, Carla Casulo, Jonathan E. Brammer, MD, Jeff Haney, Hagop Youssoufian, MD, David T. Weaver, PhD, Michael Baglio, PharmD, Jasminder Soto, Narayana Narasimhan, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 1567.

https://doi.org/10.1182/blood-2019-121401

Published: 2019

Journal Articles

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Philipp B. Staber, Marco Herling, Mar Bellido, Eric D. Jacobsen, Matthew S. Davids, Tapan Mahendra Kadia, Andrei Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Zaja, Kimmo Porkka, Gregor Hoermann, Ingrid Simonitsch-Klupp, Claudia Haferlach, Stefan Kubicek, Marius E. Mayerhoefer, Georg Hopfinger, Ulrich Jaeger, Claire Dearden

Blood (2019) 134 (14): 1132–1143.

https://doi.org/10.1182/blood.2019000402

Published: 2019

NARROW

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas

Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only